ARIAD Pharmaceuticals, Inc.

In May 2016, we entered into a Share Purchase Agreement with ARIAD Pharmaceuticals, Inc. pursuant to which we acquired ARIAD’s European subsidiaries responsible for the commercialization of Iclusig® (ponatinib) in the European Union and 22 other countries. In addition, we entered into a License Agreement granting Incyte an exclusive license to develop and commercialize Iclusig in Europe.